A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Isolation of Dendritic Cells from the Human Female Reproductive Tract for Phenotypical and Functional Studies

6.2K views

DOI:

10.3791/57100

March 13th, 2018

In This Article

Summary

We describe here a method to isolate and purify dendritic cells from different anatomical compartments in the human female reproductive tract for the evaluation of their phenotypical and functional characteristics. This method can be adapted to isolate other immune cells or dendritic cells from other mucosal tissues.

Abstract

The characterization of the human dendritic cells (DCs) resident in mucosal tissues is challenging due to the difficulty in obtaining samples, and the low numbers of DCs present per tissue. Yet, as the phenotype and function of DCs is modified by the tissue environment, it is necessary to analyze tissue resident DC populations, since blood derived DCs incompletely reflect the complexities of DCs in tissues. Here we present a protocol to isolate DCs from the human female reproductive tract (FRT) using hysterectomy specimens that allows both phenotypical and functional analyses. The protocol consists of tissue digestion to generate a single cell mixed cell suspension, followed by positive magnetic bead selection. Our tissue digestion protocol does not cleave surface markers, which allows phenotypical and functional analysis of DCs in the steady state, without overnight incubation or cell activation. This protocol can be adapted for the isolation of other immune cell types or isolation of DCs from other tissues.

Introduction

The FRT has the dual function of protecting against pathogens while allowing implantation and pregnancy1. To accomplish this, the FRT is compartmentalized, with each anatomical region displaying unique histological, immunological, and functional characteristics1.

DCs present at mucosal surfaces make contact with microbes in the lung, the gut, and the genital tract, and provide immune surveillance for potential pathogens2. DCs have the unique ability to prime naïve T-cells and trigger adaptive immune responses3. DCs in the FRT are also specialized to tolerate foreign antigens, such as those found in sperm and the developing fetus, to allow successful pregnancy4. Therefore, depending on the location, the DC phenotype and function will be distinct. It is known that DCs are strongly influenced by the tissue environment, such that their number, phenotype, and functions are modified by the tissue environment in which they reside3. Therefore, to understand the role that FRT DCs play in infectious diseases, pregnancy, and cancer in the FRT, resident DCs need to be studied, since blood derived DC models are inadequate to address the regulatory complexities found in FRT tissues.

The characterization of human tissue resident DCs is challenging due to the low numbers of cells present in mucosal tissues and the difficulty obtaining human tissue samples. DCs have been studied in the FRT using immunohistochemistry5,6, which informs about the cell location within the tissue, but precludes functional studies, and is limited in the number of identifying cell markers that can be analyzed at once. Moreover, single cell isolation protocols for flow cytometric analysis have been developed7,8,9. Some of these protocols take advantage of the migratory capacity of DCs to isolate those cells that migrate. These methods usually require overnight incubations and selection of activated DCs, but do not allow for the study of DCs in the steady state.

Here, using hysterectomy specimens, we optimized a protocol to isolate DCs from different anatomical sites in the FRT, the endometrium (EM), the endocervix (CX), and the ectocervix (ECX), that enables both phenotypical and functional analyses. Using a non-proteolytic enzymatic digestion protocol, we can proceed immediately after tissue digestion to cell isolation and flow cytometric characterization without cell activation. Using multicolor flow cytometry and adapting functional studies for low numbers of cells, we can identify and characterize rare subsets of DCs in the different sites of the FRT.

Access restricted. Please log in or start a trial to view this content.

Protocol

Studies involving human subjects were conducted according to the principles expressed in the Declaration of Helsinki. Studies were approved by Dartmouth College Institutional Review Board and the Committee for the Protection of Human Subjects (CPHS). Written informed consent was obtained before surgery from HIV-negative women undergoing hysterectomies at Dartmouth-Hitchcock Medical Center (Lebanon, NH). Trained pathologists selected tissue samples from the EM, CX, and ECX, free of pathological lesions and distant from the sites of pathology. Blood samples were obtained from volunteer healthy donors recruited at Dartmouth Hitchcock Medical Center. Blood donors were anonymous. Freshly isolated EM, CX, and ECX tissues from the operating room were transferred to Pathology for isolation and classification prior to transfer to our laboratory in separate, sterile polypropylene tubes.

1. Enzymatic Digestion of Tissues

NOTE: Use sterile materials and work in a biological safety cabinet.

  1. Prepare a modified Hank's Balanced Salt Solution (HBSS) using 1x HBSS with phenol red, 100 U/mL penicillin-streptomycin, 0.35 g/L NaHCO3, and 20 mM HEPES.
  2. Prepare the enzymatic cocktail (modified HBSS, 450 U/mL collagenase IV, 0.01% [wt/vol] deoxyribonuclease I, and 2 mg/mL D-glucose). Pass the solution through a sterile 0.22 µm filter. Ideally, prepare the digestion enzyme on the day of use, but it can be frozen at -20 °C for storage. Avoid repeated freezing and thawing cycles.
  3. Rinse the tissue with modified HBSS and place in a 100 x 15 mm2 Petri dish. Adjust the Petri dish size based on the amount of tissue available and the volume of enzyme cocktail used (see step 1.4.2 below).
    NOTE: Tissues vary in size depending on the surgical sample obtained from the pathology, ranging from 1-10 g.
  4. Physical processing with disposable scalpel and forceps:
    1. Add approximately 3 mL of digestion enzyme cocktail to the tissue to prevent drying while cutting.
    2. Use forceps to stabilize the tissue and mince with a scalpel to increase the surface area of the tissue exposed to the digestion enzyme cocktail. Cut the tissue into small pieces (< 2 mm on a side). Add sufficient digestion enzyme cocktail to cover all tissue pieces (5 mL/g of tissue). Place the lid on the Petri dish.
    3. Incubate at 37 °C with 5% CO2 on a rotator at approximately 80 rpm for 45 min. Ensure that the rotator speed thoroughly mixes the digestion enzyme cocktail without spilling or producing bubbles.
    4. Visualize the tissue preparation with an inverted light microscope with the 4X and 10X objectives.
      NOTE: After digestion, small tissue fragments and a mixed cell suspension including visible epithelial glands should be present (see Figure 1A).

2. Physical Separation of Single Cells

  1. In a sterile environment, place a taut 250 µm mesh with holder into a 150 x 15 mm2 Petri dish. Ensure that the mesh is about 0.5 cm above the surface of the Petri dish.
  2. Wet the mesh with 2 mL of modified HBSS and transfer the digested tissue onto the mesh.
  3. Using the flat surface of a 10-mL syringe plunger, gently but firmly, grind the digested minced tissue through the mesh.
    Caution: Grinding too aggressively will damage the mesh and increase cell mortality. This step will separate the epithelial cells and stromal cells (including immune cells) from the connective tissue and mucus.
  4. Once the tissue fragments have been thoroughly dispersed, elevate the mesh and the holder 2-3 cm above the Petri dish and rinse with 3 mL of modified HBSS to recover additional cells.
  5. Collect the cell suspension. Place the 20 µm mesh with holder in a Petri dish and wet with 2 mL of modified HBSS. Pour the cell suspension through the mesh holding the mesh 2-3 cm above the Petri dish, and rinse with 6 mL of modified HBSS.
    NOTE: This step will separate the epithelial sheets, which are retained on the top, from single cells that pass through the mesh. The flow-through is a mixed cell suspension, which includes immune cells and stromal fibroblasts.
  6. Collect the mixed cell suspension and centrifuge at 500 x g for 10 min. Aspirate the liquid and resuspend the pellet in 4 mL of modified HBSS for density gradient centrifugation.
  7. Layer the mixed cell suspension over 3 mL of polysucrose solution and centrifuge at room temperature at 500 x g for 30 min with no brake. Collect the white band from the top of the polysucrose solution and wash with PBS.
    NOTE: This fraction is the enriched mixed cell suspension, which is rich in immune cells and contains some stromal fibroblasts.

3. Dead Cell Removal

NOTE: If a large percentage of dead cells (> 20%) are present in the enriched mixed cell suspension after density gradient centrifugation, dead cell removal with magnetic beads is recommended. Dead cells need to be removed since they may interfere with the positive magnetic bead selection process.

  1. Count the cells using a hemocytometer on a light microscope with the 10X objective. Spin down all the cells in the enriched mixed cell suspension (500 x g, 10 min, 4 °C). Completely aspirate and discard the supernatant. Add 100 µL of dead cell removal beads per 1 x 107 total cells (live and dead), according to the manufacturer's instructions. Incubate at room temperature for 15 min.
  2. Place a 30 µm filter on the magnetic column, apply the cell suspension and allow the bead-labeled cells to fall through the magnetic column.
  3. Rinse the column with dead cell removal buffer as recommended (3 mL). Collect the flow-through containing the live cells. The range of cell recovery after dead cell removal is presented in Figure 1B.
    NOTE: These cells can be used to perform flow cytometry staining for phenotypical studies (section 5) or continue with DC isolation (section 4).

4. DC Purification by Positive Magnetic Bead Selection

  1. Following dead cell removal (step 3.2), spin the cells down, remove the supernatant, and resuspend the cell pellet in 80 µL magnetic selection buffer per 1 x 107 cells (PBS, 0.5% heat-inactivated human AB serum (HS), 2 mM EDTA).
  2. For positive selection of DC populations, add CD1a or CD14 magnetic beads according to the manufacturer's instructions (20 µL magnetic beads per 1 x 107 cells). Incubate for 15 min at 4°C.
  3. Wash the cells with the magnetic selection buffer, spin down, and remove buffer completely. Resuspend the cells in a minimum of 500 µL of magnetic selection buffer.
  4. Attach the column to the magnet and add a 30 µm filter on the top of the column to retain any remaining cell clumps. Rinse the filter and column with magnetic selection buffer as recommended.
  5. Apply the cell suspension to the column. Rinse 3 times with magnetic selection buffer.
  6. Transfer the column to a 15-mL tube, add 5 mL of magnetic selection buffer, and apply the plunger to release the selected cells from the column.
  7. To increase the purity, repeat steps 4.4-4.6 with the recovered cells using a new column. The range of cell recovery after magnetic bead selection is presented in Figure 1C.

5. Assessment of Cell Purity: Flow Cytometry and Microscopy

  1. Antibody staining for flow cytometry:
    1. Resuspend up to 1 x 106 cells in 100 µL of PBS containing 20% heat-inactivated HS to block Fc receptors, and incubate for 10 min on ice.
    2. Add the desired fluorescently labeled antibodies and the reagent for identification of dead cells (for an example, see section 6.5). Set fluorescence minus one (FMO) controls to establish the gates, and use compensation beads to prepare single stain controls for compensation. Examples of antibodies used are given in Table 1. Incubate for 20 min at 4 °C, protected from light.
    3. Wash the cells with 2 mL of magnetic selection buffer.
      NOTE: Presence of EDTA is important to avoid the formation of cell clumping for flow cytometric analysis. Spin down and discard the supernatant.
    4. Fix the cells by adding 100 µL of 2% paraformaldehyde solution per tube.
    5. Analyze the samples in by a flow cytometer10,11.
  2. Spin the column (e.g., cytospin) and use Giemsa staining to analyze morphology:
    1. Resuspend the cells in 200 µL of magnetic selection buffer.
    2. Load in a spin column and spin for 5 min. Let the slide dry completely.
    3. Fix the slide by immersion in 100% methanol for 2 min. Rinse the slide with deionized water and allow it to air dry.
    4. Perform a standard Wrights-Giemsa staining. Cover the cells with Eosin and incubate for 10 min, rinse with deionized water, and let it dry. Cover the cells with Wrights-Geimsa stain, incubate for 1 min, rinse with deionized water, and air dry.
    5. Examine the preparations with an inverted microscope (Figure 2A, 40X objective).

6. Allogeneic Stimulation Assay to Assess DC Cell Function

  1. Thaw the frozen peripheral blood mononuclear cells (PBMCs)
    1. Warm the cell culture media with 10% HS to 37 °C.
    2. Thaw the PBMCs by placing the cryotube in a 37 °C water bath, until a small amount of frozen cell media remains in the cryotube. In a sterile environment, transfer the contents of the cryotube to 10 mL of pre-warmed cell culture media with 10% HS in a 15-mL tube.
    3. Centrifuge at ~ 500 x g for 7 min. Remove the media, disperse the pellet, resuspend the PBMCs in 10 mL of cell culture media with 10% HS, and centrifuge the cells.
    4. Repeat the wash step a third time. Count the cells.
  2. Naïve T-cell selection:
    1. Use a negative selection magnetic antibody cell selection kit to isolate naïve T-cells according to the manufacturer's protocol.
    2. After isolation, check the purity using CD45RA and CCR7 antibodies.
      NOTE: Typical purity is > 99% naïve T-cells.
  3. Naïve T-cell proliferation dye staining:
    1. Prepare 600 µL of 2x solution of cell proliferation dye, protecting the dye from exposure to light.
    2. Wash the naïve T-cells 2x with PBS. Resuspend cells in 500 µL PBS.
    3. While gently vortexing the cells in the biosafety cabinet, add 500 µL of proliferation dye to the naïve T-cells.
    4. Incubate the cells for 10 min at 37°C.
    5. Stop the cell labeling by adding 5 mL of cell culture media with 10% HS to the cells. Incubate on ice for 5 min, protected from light.
    6. Centrifuge the cells at ~ 500 x g for 7 min, aspirate the media, and resuspend the cells in 4 °C of cell culture media with 10% HS. Repeat two more times for a total of 3 washes. Take an aliquot of cells to count prior to the last centrifugation.
      NOTE: Typically, final naïve T-cell numbers will range between 5% and 15% of the initial PBMC cell count.
    7. Resuspend the cells with the cell culture media with 10% HS at the desired cell concentration.
  4. DC-allogeneic naïve T-cell co-culture:
    1. Plate the isolated DCs and naïve T-cells in a 96-well, round-bottom plate, at a 1:15 ratio of DCs to T-cells. Ensure that the optimal number for DCs ranges between 3,000 and 5,000 cells/well.
    2. Centrifuge the plate at ~ 500 x g for 3 min to ensure the cells are located at the center of the well. Cell-to-cell contact is important for proper signaling to occur.
    3. Incubate at 37 °C for 6 days. Monitor the cluster of cells, which appear in the wells as proliferation occurs, with microscopy (Figure 3A).
  5. Flow cytometry staining to assess proliferation:
    1. After 6 days, cells can be examined by flow cytometry. Stain the co-culture for flow cytometry.
    2. Prepare a 2x solution of yellow viability dye (maximum emission 572 nm) in PBS.
      NOTE: The use of PBS without serum is important, as serum proteins interfere with the dye).
    3. Centrifuge the plate with cells at ~ 500 x g for 5 min.
    4. Remove 100 µL of supernatant.
      NOTE: At this point collect and store the supernatant for separate analysis of soluble factors.
    5. Wash the cells two times with PBS: add 150 µL/well of PBS, centrifuge at ~ 500 x g for 5 min, remove 150 µL of supernatant with a pipette. Ensure that there is 50 µL of supernatant remaining in each well.
    6. Add 50 µL of 2x viability dye to each well. Incubate at room temperature for 10 min, protected from light.
    7. During the incubation, prepare a master mixture of desired antibody markers. For example: CD3 APC/Cy7, CD4 PE, CD8 FITC, etc.
    8. Add the antibody mixture to each well. Incubate at room temperature for 10 min, protected from light.
    9. Wash the cells 2x with PBS + 2% HS: add 150 µL/well of PBS + 2% HS. Centrifuge at ~ 500 x g for 5 min. Remove 150 µL of supernatant with a pipette.
    10. Fix the cells by adding 100 µL/well of 2% para-formaldehyde. If needed: transfer the cells and media to polypropylene flow cytometry tubes. Tubes can be kept at 4 °C and protected from the light, until the flow cytometric analysis.
    11. Read tubes in a flow cytometer.

Access restricted. Please log in or start a trial to view this content.

Results

Following tissue digestion, the release of epithelial sheets and glands can be observed, as shown in Figure 1A; this is a positive control that indicates the enzymatic digestion was successful. The number of total viable cells and DCs recovered per gram of tissue are also shown in Figure 1B and Figure 1C, respectively. Immune cells represent between 5-30% of the stromal cells prior to density centrif...

Access restricted. Please log in or start a trial to view this content.

Discussion

Mucosal DCs are a rare cell population strongly influenced by the tissue environment, which changes their phenotype and function once they enter the tissues3. While blood derived DCs are a very useful model, they do not fully represent the diversity of DC populations found in tissues. Therefore, to understand the unique characteristics of mucosal DCs, isolation of primary cells from tissues is necessary. Isolation of DCs from different anatomical sites in the FRT offers the opportunity to study DC...

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have nothing to disclose

Acknowledgements

Study supported by NIH grants AI102838 and AI117739 (CRW). We thank Richard Rossoll for technical assistance. Flow cytometric analysis was carried out in DartLab, the Shared Resource at Dartmouthsupported by (P30CA023108-37) and (P30GM103415-15).

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
Hank's Balanced Salt Solution (HBSS)HycloneSH30015.03
Penicillin-streptomycinHycloneSV30010
HEPES (1M)Hyclone15630-080
Collagenase IVSigmaC5138
Deoxyribonuclease IWorthington BiochemicalLS002140
D-glucoseSigma Aldritch50-99-7
0.22 um Stericup 500 mL  filterMilliporeSCGPU05RE
100mm x 15mm polystyrene petri dishFisherbrandFB0875712
150mm x 15mm polystyrene petri dishFisherbrandFB0875714
150mm x 25mm polystyrene dishCorning430599Treated cell culture dish
Isotemp IncubatorFisher ScientificFICO3500TABB5.0% CO2
American Rotator VAmerican DADER4140
250 um nylon meshSefar03-250/50
20 um nylon meshSefar03-20/14
Beckman GS-6R CentrifugeBeckman358702
X-VIVO 15 with Gentamicin L-Gln, Phenol Red, 1 LLonza04-418Q
Human AB SerumValley BiomedicalHP1022
Histopaque-1077Sigma Aldritch10771
Phosphate Buffer Solution (PBS)National DiagnosticsCL-253pH 7.4
Dead Cell Removal KitMiltenyi Biotec130-090-101
Pre-separation filter (30um)Miltenyi Biotec130-041-407
LS columnMiltenyi Biotec130-042-410
Quadro MACS SeparatorMiltenyi Biotec130-090-976
MACS multi-standMiltenyi Biotec130-042-303
EDTAUSB15694
CD1a Microbeads, humanMiltenyi Biotec130-051-001
CD14 Microbeads, humanMiltenyi Biotec130-050-201
eFluor 670 cell proliferation dyeeBiosciences65-0840-85
96 well round bottom plateFalcon9/8/2866
Zombie yellow viability dyeBiolegend423104
CD3 APC/Cy7, anti-humanTonbo Biosciences25-0038-T100
CD4 PE, anti-humaneBiosciences12-0048-42
CD8a FITC, anti-humanTonbo Biosciences35-0086-T100
Gallios Flow CytometerBeckman Coulter Life SciencesB4361810 color, VBR
MACSquant Analyzer 10Miltenyi Biotec130-096-3438 color, VBR

References

  1. Wira, C. R., Rodriguez-Garcia, M., Patel, M. V. The role of sex hormones in immune protection of the female reproductive tract. Nat Rev Immunol. 15 (4), 217-230 (2015).
  2. Banchereau, J., Steinman, R. M. Dendritic cells and the control of immunity. Nature. 392 (6673), 245-252 (1998).
  3. Schlitzer, A., McGovern, N., Ginhoux, F. Dendritic cells and monocyte-derived cells: Two complementary and integrated functional systems. Semin Cell Dev Biol. 41, 9-22 (2015).
  4. Tagliani, E., Erlebacher, A. Dendritic cell function at the maternal-fetal interface. Expert Rev Clin Immunol. 7 (5), 593-602 (2011).
  5. Kaldensjo, T., et al. Detection of intraepithelial and stromal Langerin and CCR5 positive cells in the human endometrium: potential targets for HIV infection. PLoS One. 6 (6), e21344(2011).
  6. Schulke, L., Manconi, F., Markham, R., Fraser, I. S. Endometrial dendritic cell populations during the normal menstrual cycle. Hum Reprod. 23 (7), 1574-1580 (2008).
  7. Ballweber, L., et al. Vaginal langerhans cells nonproductively transporting HIV-1 mediate infection of T cells. J Virol. 85 (24), 13443-13447 (2011).
  8. Hladik, F., et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity. 26 (2), 257-270 (2007).
  9. Duluc, D., et al. Functional diversity of human vaginal APC subsets in directing T-cell responses. Mucosal Immunol. 6 (3), 626-638 (2013).
  10. Herzenberg, L. A., Tung, J., Moore, W. A., Parks, D. R. Interpreting flow cytometry data: a guide for the perplexed. Nat Immunol. 7 (7), 681-685 (2006).
  11. Juno, J. A., Boily-Larouche, G., Lajoie, J., Fowke, K. R. Collection, isolation, and flow cytometric analysis of human endocervical samples. J Vis Exp. (89), (2014).
  12. Givan, A. L., et al. Flow cytometric analysis of leukocytes in the human female reproductive tract: comparison of fallopian tube, uterus, cervix, and vagina. Am J Reprod Immunol. 38 (5), 350-359 (1997).
  13. Rodriguez-Garcia, M., et al. Dendritic cells from the human female reproductive tract rapidly capture and respond to HIV. Mucosal Immunol. 10 (2), 531-544 (2017).
  14. Rodriguez-Garcia, M., Barr, F. D., Crist, S. G., Fahey, J. V., Wira, C. R. Phenotype and susceptibility to HIV infection of CD4+ Th17 cells in the human female reproductive tract. Mucosal Immunol. 7 (6), 1375-1385 (2014).
  15. Shen, Z., Rodriguez-Garcia, M., Ochsenbauer, C., Wira, C. R. Characterization of immune cells and infection by HIV in human ovarian tissues. Am J Reprod Immunol. , (2017).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Tags

Dendritic Cell IsolationTissue DigestionMagnetic Bead SelectionFlow Cytometry AnalysisCD1a CD14 MarkersDensity Gradient CentrifugationDead Cell RemovalCell Suspension PreparationPhenotypical Functional Studies